| Topic | People | Description |
|---|---|---|
| red cell disorders and pathologic erythropoiesis |
Lucia De Franceschi
|
My scientific activity has focused on red cell pathologies, normal and pathologic erythropoiesis, hemoglobinopathies such as β-thalassemic syndromes and sickle cell disease (SCD) and hereditary rare anemias (i.e.: stomatocytosis, CDAII). An additional area of investigation is chorea-acanthocytosis and McLeod syndrome, which are neurodegenerative disorders involving also the erythroid compartment (Blood 118: 5652-63, 2011; Blood 128: 2976, 2016; J Neurosci 36: 12027, 2016). Through highly productive collaborations and keywork in my laboratory, my research has resulted in a number of breakthrough technologies and discoveries. |
| immunophenotype of acute and chronic leukemias |
Mauro Krampera
|
immunophenotypic characterization of acute and chronic leukemias |
| immunophenotype in malignant and non-malignant conditions |
Mauro Krampera
|
immunophenotypic and functional characterization and sorting of lymphoid subsets in peripheral blood and normal hemato-lymphopoietic tissues and in a number of malignant and non-malignant conditions |
| flow-cytometric monitoring of minimal residual disease |
Mauro Krampera
|
clinical application of flow-cytometric monitoring of minimal residual disease (MRD) in acute leukemia patients; he coordinated the use of this approach also in an Italian multicentre study (GIMEMA LAL0496) |
| myeloproliferative neoplasms |
Massimiliano Bonifacio
|
Efficacy and safety of target therapies in myeloproliferative neoplasms defined by specific genetic and/or molecular markers (i.e. BCR-ABL for chronic myeloid leukemia, KIT for systemic mastocytosis, JAK2, MPL and CALR for Philadelphia-negative myeloproliferative neoplasms); predictive biomarkers of target therapies; immunotherapy of hematologic diseases. |
| Experimental studies in leukemias, lymphomas and multiple myeloma |
Mauro Krampera
Cristina Tecchio |
In vitro studies on new therapeutic agents |
